Adc Therapeutics Sa's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Adc Therapeutics Sa's ROI in the second quarter of 2026?
Adc Therapeutics Sa recorded a cumulative net loss of $-97 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -37.5%.

Within the Healthcare sector 324 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3554 to 3667.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-4.57 %	5.06 %	3.53 %	-4.82 %	38.28 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	193	277	291	273	306
Return On Investment (TTM)	-37.5 %	-47.79 %	-50.84 %	-62.14 %	-62.76 %
ADCT's Overall Ranking	# 3667	# 3554	# 2680	# 3325	# 3500
Seq. Investment Change TTM	-9.85 %	2.18 %	4.42 %	-0.79 %	-0.75 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-97	-137	-143	-167	-170

ADCT Company Profile >> Back to ADCT Roi Comparisons >> See Annual ADCT Return On Investment

Return On Investment ADCT's Ranking
Within:	No.
Industry	# 122
Sector	# 325
Overall	# 3667

Return On Investment Statistics
High	Average	Low
14.78 %	-56.27 %	-648.95 %
(July 31, 2005)		(Dec 31 2023)

Financial Statements
Adc Therapeutics Sa's II. Quarter Investments	$ 193 Millions	ADCT's Balance sheet
Adc Therapeutics Sa's II. Quarter Income	$ -17 Millions	Quarterly ADCT's Income Statement
ADCT's Income by Division		See ADCT's Income by Division

ADCT Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	259	243	288	535	519
Y / Y Investment Growth	6.41 %	-15.62 %	-46.05 %	3.06 %	9.61 %
Net Income in Millions	-143	-158	-240	-156	-230
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-55.07 %	-64.85 %	-83.22 %	-29.14 %	-44.34 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ADCT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ADCT's Competitors
Subscribers only: Roi for Adc Therapeutics Sa's Suppliers
Subscribers only: Return On Investment for ADCT's Customers

Other Ratios
ADCT's Roa	ADCT's Inventory Turnover Ratio	ADCT's Growth Rates	ADCT's Dividend Statistics
	ADCT's Profitability Ratios	ADCT's Asset Turnover Ratio	ADCT's Dividend Growth
ADCT's Roe	ADCT's Valuation Ratios	ADCT's Financial Strength Ratios	ADCT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:39:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.